O G Trifanescu1,2, L N Gales1,2, R A Trifanescu3,4, R M Anghel1,2. 1. "Prof. Dr. Al. Trestioreanu" Institute of Oncology, Radiotherapy 2, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2. Department of Medical Oncology, Bucharest, Romania. 3. Department of Endocrinology, Bucharest, Romania. 4. "C. I. Parhon" Institute of Endocrinology, Department of Pituitary Pathology, Bucharest, Romania.
Abstract
AIMS: To assess the impact of prognostic factors on the outcome of ovarian carcinoma (OC) and to determine the difference between pre and postmenopausal patients. DESIGN: Retrospective cohort, single centre study. SUBJECTS AND METHODS: One-hundred-sixty patients with stage IC-IV OC diagnosed between 2004-2016 were included. Treatment consisted in primary surgery followed by adjuvant chemotherapy (n=127, 79.4%), neoadjuvant chemotherapy followed by surgery (n=27, 16.9%) and chemotherapy alone (3.7%). RESULTS: At diagnosis 62 patients (38.8%) were premenopausal. Most patients presented with advanced OC (stage III/IV, 63.1%). After a median follow-up of 60 months, median progression free survival (PFS) for all stages was 36 months and median overall survival (OS) was 96 months. Postmenopausal patients had a poorer oncologic outcome compared with pre-menopausal women (PFS 24 vs. 72 months, p=0.0001, HR=2.32). Other clinical prognostic factors identified were performance status 1 vs. 0 (p=0.0001), ascites (p=0.027). Pathology prognostic factors were tumour grade (G1 vs. G2 and G3, p=0.0001) and endometrioid subtype compared to serous (p=0.008). Patients with residual disease after surgery had an increased risk of recurrence and death (HR=6.1, p=0.0001 and HR=4.2, p=0.0001). CONCLUSION: Premenopausal patients had a better oncologic long-term outcome and stage, ascites, grading, residual disease, were independent prognostic factors.
AIMS: To assess the impact of prognostic factors on the outcome of ovarian carcinoma (OC) and to determine the difference between pre and postmenopausal patients. DESIGN: Retrospective cohort, single centre study. SUBJECTS AND METHODS: One-hundred-sixty patients with stage IC-IV OC diagnosed between 2004-2016 were included. Treatment consisted in primary surgery followed by adjuvant chemotherapy (n=127, 79.4%), neoadjuvant chemotherapy followed by surgery (n=27, 16.9%) and chemotherapy alone (3.7%). RESULTS: At diagnosis 62 patients (38.8%) were premenopausal. Most patients presented with advanced OC (stage III/IV, 63.1%). After a median follow-up of 60 months, median progression free survival (PFS) for all stages was 36 months and median overall survival (OS) was 96 months. Postmenopausal patients had a poorer oncologic outcome compared with pre-menopausal women (PFS 24 vs. 72 months, p=0.0001, HR=2.32). Other clinical prognostic factors identified were performance status 1 vs. 0 (p=0.0001), ascites (p=0.027). Pathology prognostic factors were tumour grade (G1 vs. G2 and G3, p=0.0001) and endometrioid subtype compared to serous (p=0.008). Patients with residual disease after surgery had an increased risk of recurrence and death (HR=6.1, p=0.0001 and HR=4.2, p=0.0001). CONCLUSION: Premenopausal patients had a better oncologic long-term outcome and stage, ascites, grading, residual disease, were independent prognostic factors.
Authors: Jean S Fleming; Clare R Beaugié; Izhak Haviv; Georgia Chenevix-Trench; Olivia L Tan Journal: Mol Cell Endocrinol Date: 2005-11-16 Impact factor: 4.102
Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Patricia G Moorman; Brian Calingaert; Rachel T Palmieri; Edwin S Iversen; Rex C Bentley; Susan Halabi; Andrew Berchuck; Joellen M Schildkraut Journal: Am J Epidemiol Date: 2008-02-25 Impact factor: 4.897
Authors: Kehinde Sharafadeen Okunade; Adebola A Adejimi; Ephraim O Ohazurike; Omolola Salako; Benedetto Osunwusi; Muisi A Adenekan; Aloy O Ugwu; Adaiah Soibi-Harry; Olayemi Dawodu; Adeyemi A Okunowo; Rose I Anorlu; Jonathan S Berek Journal: JCO Glob Oncol Date: 2021-01